MFDS advises additional warnings to 9 antidepressants

Published: 2013-05-07 06:57:00

Updated: 2013-05-07 06:57:00

Pharmaceutical companies producing antidepressants must include a warning with their products that state the drugs may develop a life-threating serotonin syndrome in patients receiving a concomitant administration with an antidepressant and a MAO inhibitor. MAO inhibitors include isocarboxazid, l...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK